| Home Market Dynamics Sector Analysis Company Insights AI Investing Strategies Contact Us Login |
| Gilead Sciences is experiencing a pivotal moment in its product development pipeline, particularly with the anticipated approval of lenacapavir for HIV prevention. This development is viewed as a significant advancement, enhancing the company's competitive edge and expanding its product offerings. The positive sentiment around lenacapavir reflects strong expectations for its market potential. However, regulatory hurdles and competition in the HIV treatment space could pose challenges to the successful launch and adoption of new products. |
| The price action of Gilead Sciences (GILD) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The market sentiment at 0.4 is modestly bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.There is no clear direction for GILD since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 0.6, and the negative at -0.2 on 2025-04-17. The forces of and Valuation Sentiment (-1) will drive down the price. The forces of Stock Price Trend (0), Sector Price Trend (0), Price Level Sentiment (0), Option Sentiment (0), Market Risk Appetite (0), and Sentiment towards Fundamentals (3.6) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| GILD | |||||||||||||
| Date | Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Hourly Trend | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-04-17 | 0%(0%) | 0 | 0% | 0.4 | 3.6 | -1 | |||||||
| 2025-04-16 | 0%(0%) | 0 | 0% | 0.4 | 3.5 | -1 | |||||||
| 2025-04-15 | 0%(0%) | 0 | 0% | 0.4 | 3.3 | -1 | |||||||
| 2025-04-14 | 0%(0%) | 0 | 0% | 0.4 | 3.3 | -1 | |||||||
| 2025-04-13 | 0%(0%) | 0 | 0% | 0.5 | 4 | -1 | |||||||
| 2025-04-12 | 0%(0%) | 0 | 0% | 0.5 | 4 | -1 | |||||||
| 2025-04-11 | 0%(0%) | 0 | 0% | 0.5 | 4 | -1 | |||||||
| 2025-04-10 | 0%(0%) | 0 | 0% | 0.4 | 3.4 | -1 | |||||||
| 2025-04-09 | 0%(0%) | 0 | 0% | 0.4 | 3.3 | -1 | |||||||
| 2025-04-08 | 0%(0%) | 0 | 0% | 0.4 | 3.2 | -1 | |||||||
| Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | |||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | |||||||||||||
| 2025-09-29 00:33:05 Analysts suggest a wait-and-watch approach, indicating concerns over future earnings stabilization. |
| 2025-09-29 00:33:05 Gilead's leading position in the HIV market is acknowledged, with possible challenges ahead that could impact its future standing. |
| 2025-09-29 00:33:05 There is a cautious approach advised for investors regarding GILD stock, with sentiments suggesting waiting before making decisions. |
| 2025-09-29 00:33:05 The anticipation of lenacapavir's approval could significantly enhance Gilead's product lineup, providing a competitive advantage. |
| 2025-09-29 00:33:05 Expectations around Gilead Sciences' upcoming earnings report are positive, indicating potential growth. |